­
­
­
­

Inventi Impact: Gastroenterology

Articles

  • Inventi:hgst/32403/20
    Predictors of Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization: Role of Hepatocyte Growth Factor
    Research 2020 : October - December
    Amr Mohamed Zaghloul, Ahmed Sedky, Ali Hussein Mohammed, Samer A El-Sawy, Ahmed Abd El Rady Ahmed, Emad Eldin Nabil

    Background: Hepatocellular carcinoma is the third leading cause of tumor\nrelated mortality and develops mostly in patients with chronic liver disease and\nliver cirrhosis. Human hepatocyte growth factor (HGF) is produced in various\norgans of the body and is characterized as a multifunctional factor with various\nbiologic activities. Aim: Our aim was to investigate the predictive factors of\nrecurrence specially the role of HGF in patients with HCC treated with TACE.\nPatients and Methods: one hundred HCC patients treated by TACE who\nachieved complete response were included and divided into two groups according\nto disease free survival (DFS) status at 1 year: the non-early recurrence\n(NER) group (1) and the early recurrence (ER) group (2). Univariate binary\nlogistic regression analysis for the possible risk factors of recurrence showed\nthat AFP, multinodularity and HGF level were significant. Conclusion: high\nAFP, multinodularity and high HGF were inter-related possible risk factors for\n1-year recurrence of HCC in patients with initial remission following TACE.

    How to Cite this Article
    Attribution/ CC Compliant Citation: Zaghloul, A.M., Sedky, A., Mohammed, A.H., El-Sawy, S.A., El Rady Ahmed, A.A. and Nabil, E.E. (2020)\nPredictors of Recurrence of Hepatocellular Carcinoma after Transarterial Chemoembolization: Role of Hepatocyte Growth Factor. Open\nJournal of Gastroenterology, 10, 151-165; https://doi.org/10.4236/ojgas.2020.106016; http://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text